-
Int J Urol: How effective is cabazide in patients with metastatic castration-resistant prostate cancer?
Time of Update: 2022-10-12
In patients with metastatic castration-resistant prostate cancer treated with cabatarace, poor status, anemia, and mid-high granulocyte-lymphocyte ratio are risk factors for poor prognosis.
In patients with metastatic castration-resistant prostate cancer treated with cabatarace, poor status, anemia, and mid-high granulocyte-lymphocyte ratio are risk factors for poor prognosis.
-
Science Advances: First confirmed: epigenetic drug EZH2 inhibitors, which treat bladder cancer by activating the immune system
Time of Update: 2022-10-12
Next, the team used the commercially available EZH2 inhibitor Tazemetostat to treat mice with bladder cancer, and the results showed that tazestat filled the bladders of mice with immune cells.
-
Deepening the Impression - A Case of Inflammatory Myofibroblastic Tumor of Esophagus and Gastric
Time of Update: 2022-10-12
CT examination showed that the esophageal wall in the lower esophagus and the gastric wall in the cardia area were significantly thickened unevenly, and the esophageal cavity was narrowed; a mass of high-density shadow was seen at the fundus of the stomach, no tumor grew significantly outside the wall, and no obvious surrounding lymph nodes were found ( Figure C) .
-
Radiology: Microcalcification and peritumoral edema predict the prognosis of neoadjuvant chemotherapy for Luminal breast cancer
Time of Update: 2022-10-12
10 years after surgery, the patient is still alive without distant metastasesIn this study, predictive models that combined imaging and clinicopathological variables showed good resolution for the prognosis of patients with Luminal breast cancer receiving neoadjuvant chemotherapy.
-
J Clin Oncol: Toripalimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer
Time of Update: 2022-10-12
Progression-free survival rates in both groupsAt the time of the final PFS analysis, PFS was significantly longer in the Toripalimab group than in the placebo group (median PFS: 8.
-
The project kick-off meeting of the "Report on the Development of Cancer Science Popularization in China" was successfully held
Time of Update: 2022-10-12
Zhang Fabao, chairman of Mace Medicine, pointed out in his speech that under the leadership of the China Association for Science and Technology and the China Anti-Cancer Association, and under the personal supervision of Director Tian Yantao, the Metz medical team is deeply honored to participate in the "China Oncology Science Popularization Work Development Report" project.
-
J Clin Oncol: Prognosis for patients with recurrent high-risk neuroblastoma with I/T/DIN/GM-CSF
Time of Update: 2022-10-12
Progression-free survival in patients who achieved objective remission with I/T/DIN/GM-CSF therapyPatients were treated with a median course of 4.
Progression-free survival in patients who achieved objective remission with I/T/DIN/GM-CSF therapyPatients were treated with a median course of 4.
-
European Radiology: Lineage plot of survival prognosis for triple-negative breast cancer
Time of Update: 2022-10-12
The nominative graph model proposed in this study integrates three variables of postoperative adjuvant chemotherapy, axillary lymph node load and malignant acoustic performance, and can be used as an effective imaging tool to predict the survival prognosis of patients with TNBC.
-
Cancer Cell: Analysis of rare susceptibility mutations in lung cancer based on genome-wide analysis of 6,004 Chinese
Time of Update: 2022-10-12
Research Highlights:We conducted the largest non-small cell lung cancer (NSCLC) whole genome sequencing (WGS) study to date, with 6,004 Chinese individuals and 23,049 individuals genotyped by SNP arrays.
-
Int J Radiat Oncol Biol Phys: How effective is IVH with or without brachytherapy in patients with very high-risk prostate cancer?
Time of Update: 2022-10-12
Very high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with a high risk of long-range progression in which systematic intensive therapy with abiraterone or docetaxel reduces specific mortality (PCSM) and distal metastases (DM) in men receiving in vitro irradiation radiation therapy (EBRT) and androgen deprivation therapy (ADT).
-
ESMO 2022: GMO herpes virus provides a deep secondary blow to advanced cancer
Time of Update: 2022-10-12
""The results of our preliminary trials suggest that genetically engineered forms of herpes virus may be a new treatment option for some patients with advanced cancer — including those who haven't responded to other forms of immunotherapy.
-
【One case per day】 Liver metastases
Time of Update: 2022-10-12
The pathology of liver metastases is similar to the primary lesion, such as their blood supply is the same as that of the primary tumor2.
The pathology of liver metastases is similar to the primary lesion, such as their blood supply is the same as that of the primary tumor2.
-
Prostate: Which is better for radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer?
Time of Update: 2022-10-12
Recently, researchers from Japan published an article in Prostate that used a propensity score matching analysis to compare the long-term effects of radical prostatectomy (RP) and low-dose rate brachytherapy (LDR-BT) in patients with clinically localized, medium-risk prostate cancer (PCa).
-
J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma
Time of Update: 2022-10-12
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
-
Eur Urol Focus: Chromosomal instability of cell-free DNA can serve as a prognostic biomarker for androgen deprivation in the treatment of metastatic hormone-sensitive prostate cancer
Time of Update: 2022-10-12
Although patients with metastatic hormone-sensitive prostate cancer (mHSPC) can be treated with androgen deprivation therapy (ADT), metastases can still progress to anti-prostate cancer (mCRPC).
Sep 2022 Although patients with metastatic hormone-sensitive prostate cancer (mHSPC) can be treated with androgen deprivation therapy (ADT), metastases can still progress to anti-prostate cancer (mCRPC).
-
MMR: Prof. Yi's team elucidated a new molecular mechanism for the malignant progression of esophageal cancer
Time of Update: 2022-10-12
1186/s40779-022-00412-0 Recently, the team of Professor Hu Yi, director of the Department of Oncology Medicine of the Fifth Medical Center of the PLA General Hospital, and the team of Professor Yan Xiaolong of the Second Affiliated Hospital of the Air Force Military Medical University published a report entitled "Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive" in the international academic journal Military Medical Research Feedback loop and suppressing the USP10-maintained HDAC7 protein stability" research paper.
-
Hangzhou 41-year-old woman with advanced gallbladder cancer and lost the opportunity for chemotherapy! In fact, there were signs a year ago
Time of Update: 2022-10-12
Advanced gallbladder cancer was detected, and there was no chance of surgical chemotherapyA year ago, I didn't pay attention to the physical examinationMs. Yang is usually in good health.
-
Prostate: Does metformin have an effect on mortality in Asian prostate cancer with diabetes who undergo androgen deprivation therapy?
Time of Update: 2022-10-12
Sep 2022 Globally, prostate cancer (PCa) was the second most common cancer and the fifth leading cause of cancer death among men in 2012.
Sep 2022 Globally, prostate cancer (PCa) was the second most common cancer and the fifth leading cause of cancer death among men in 2012.
-
A complete review of the nine major drug targets for non-small cell lung cancer
Time of Update: 2022-10-12
At present, EGFR-TKI has developed into the fourth generation, and a total of 8 drugs have been launched .
At present, EGFR-TKI has developed into the fourth generation, and a total of 8 drugs have been launched .
-
Lancet Sub-Journal: Efficacy and safety of KL-A167 in patients with recurrent/metastatic nasopharyngeal carcinoma in China
Time of Update: 2022-10-12
Dynamic changes in plasma EBV DNA are significantly associated with objective response rates and progression-free survival.
Dynamic changes in plasma EBV DNA are significantly associated with objective response rates and progression-free survival.
Dynamic changes in plasma EBV DNA are significantly associated with objective response rates and progression-free survival.
